中國寶安(000009.SZ):貝特瑞擬投資50億元建年產4萬噸硅基負極材料項目
格隆匯2月16日丨中國寶安(000009.SZ)公佈,公司下屬子公司貝特瑞新材料集團股份有限公司(“貝特瑞”)擬與深圳市光明區人民政府簽署《貝特瑞高端鋰離子電池負極材料產業化項目投資合作協議》,擬在深圳市光明區內投資建設年產4萬噸硅基負極材料項目,項目預計總投資50億元。
項目在取得深圳市光明區的建設用地後,擬分期建設,於2023年12月底前建成投產年產1.5萬噸硅基負極材料產能;於2028年前實現年產4萬噸硅基負極材料產能全面達產。項目預計總投資50億元,其中固定資產投資(包括但不限於土地、廠房、設備等)約為35億元,流動資金預計約為15億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.